Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease
作者:Wandong Liu、Juan Wang、Suyun Wang、Kairui Yue、Yu Hu、Xiaochun Liu、Lihao Wang、Shengbiao Wan、Ximing Xu
DOI:10.1016/j.bioorg.2023.106830
日期:2023.11
scaffolds of PLpro and Mpro inhibitors. The representative compounds 6c and 7e exhibited excellent PLpro inhibition with percent inhibition of 42.9% and 44.9% at 50 nM, respectively. The preliminary enzyme kinetics experiment and fluorescent labelling experiment results determined that 6c was identified as a covalent PLpro inhibitor, while 7e was a non-covalent inhibitor. Molecular docking and dynamics
全球冠状病毒病2019(COVID-19)大流行仍然威胁着人类健康和公共安全,迫切需要开发有效的抗病毒药物。SARS-CoV-2 主蛋白酶 (Mpro) 和木瓜蛋白酶 (PLpro) 是病毒复制中的重要蛋白质,也是有希望的治疗靶点。此外,PLpro 还通过从 ISGylated 宿主蛋白中裂解泛素和干扰素刺激的基因产物 15 (ISG15) 来调节宿主免疫反应。在本报告中,我们确定[1,2]硒唑并[5,4- c ]吡啶-3(2H)-一和苯并[ d ]异噻唑-3(2H)-一作为PLpro和Mpro抑制剂的有吸引力的支架。代表性化合物6c和7e表现出优异的 PLpro 抑制作用,在 50 nM 时抑制百分比分别为 42.9% 和 44.9%。初步的酶动力学实验和荧光标记实验结果确定6c为共价PLpro抑制剂,7e为非共价PLpro抑制剂。分子对接和动力学模拟表明,6c和7e与 PLpro 的 Zn